Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00308581
Status:
COMPLETED
Last Update Posted:
2018-08-07
First Post:
2006-03-28
Brief Title:
Certolizumab in Crohns Disease Patients With Loss of Response or Intolerance to Infliximab
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohns Disease Patients With Prior Loss of Response or Intolerance to Infliximab
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03559660
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
None
Brief Summary:
To assess the clinical efficacy of subcutaneous sc certolizumab pegol administration over 26 weeks in patients suffering from Crohns Disease CD and previously treated with infliximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract number 2005-004104-37 | None | None | None |